KalshiCheck availabilityKYC required2% feeVerified resolution dataFairly calibratedData quality warningNo trading activity
Data as of Sep 9, 2026, 10:40 AM UTC · policy pm-quality-3
Current implied probability
Above 1025000 0%Leader of 5 outcomes
Market quality
39 / 100
Low quality24h Volume
—
Liquidity
—
Liquidity unknownSpread
4.0 pt
Moderate spreadMarket data
Updated 7 minutes ago
Aug 13, 26, 2:25 AM UTCMar 5, 27, 5:00 AM UTC
Trends
0%
0%
0%
0%
0%
Related Markets
Related questions for context, not a comparison of equivalent contracts.
Rules
If Natera, Inc. reports the named outcome tests processed in Q3 2026, then the market resolves to Yes.
Settles via:Fiscal.ai
- Kalshi is not affiliated, associated, authorized, endorsed by, or in any way officially connected with the underlying company.
- All trademarks, logos, and brand names are the property of their respective owners.
Open markets
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No-0.2pt97%
- Yes+0.2pt3%
- Total Vol
- $18.1M
- 24h Vol
- $23.7K
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+0.6pt4%
- Total Vol
- $1.9M
- 24h Vol
- $9.3K
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+4.0pt65%
- September41%
- June28%
- Total Vol
- $97.8K
POLYMARKETEbola pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Total Vol
- $759.2K
- 24h Vol
- $4K
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-3.0pt59%
+2 more outcomes
- Total Vol
- $1M
- 24h Vol
- $3.5K
POLYMARKETNew pandemic in 2026?
- No+1.0pt94.1%
- Yes-1.0pt5.9%
- Total Vol
- $1.1M
- 24h Vol
- $1.5K
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will 3 mg THC beverages be federally legal to sell?
- Measles cases in U.S. in 2026?
- Cyclosporiasis cases reported in the US in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve CagriSema?
- When will the FDA reclassify BPC-157 to Category 1?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
Frequently asked questions
- What are the current odds for Natera tests processed in Q3?
- Kalshi prices Above 1025000 at 0% as of September 9, 2026.
- When does Natera tests processed in Q3 resolve?
- Natera tests processed in Q3 is scheduled to resolve on March 5, 2027.
- How is Natera tests processed in Q3 settled?
- Kalshi settles this market as follows: If Natera, Inc. reports the named outcome tests processed in Q3 2026, then the market resolves to Yes.